New hope for hard-to-treat colon cancer: combo attack with immunotherapy and radiation
NCT ID NCT07502014
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests whether adding an immunotherapy drug (iparomlimab and tuvonralimab) and targeted radiation to a standard targeted therapy (fruquintinib) can help people with metastatic colorectal cancer that has spread to a few spots. The trial will enroll 60 adults who have already tried at least two prior treatments. Half will get the new combo, half will get fruquintinib alone, and researchers will compare how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
iparomlimab and tuvonralimab (QL1706) plus fruquintinib plus radiotherapy
What this could lead to
If successful, this could offer a new treatment option for people with advanced colorectal cancer that has stopped responding to earlier therapies.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. The combination also carries risks of immune-related side effects and radiation toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.